Healthcare ❯ Pharmaceuticals ❯ Weight Loss Drugs

GLP-1 Drugs

Mounjaro Mounjaro and Zepbound Eli Lilly Wegovy and Ozempic Eli Lilly and Company Market Competition Eli Lilly and Novo Nordisk Tirzepatide Ozempic Novo Nordisk Market Growth Semaglutide Misuse Concerns Cigna

10 ARTICLES

3w ago

Generics and Pills Expand Access to GLP‑1s, but Uptake and Coverage Remain Uneven

New oral drugs and cheaper generics are driving interest while cost, injection aversion, uncertain long‑term effects and high payer bills are prompting cautious prescribing and tighter employer coverage.

9 ARTICLES

3mo ago

Eli Lilly Shifts to Access-First Strategy on GLP-1 Strength

GLP-1 Drugs

Generics and Pills Expand Access to GLP‑1s, but Uptake and Coverage Remain Uneven

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

Eli Lilly Jumps on GLP‑1 Momentum as 2026 Outlook Beats and Targets Rise

Eli Lilly’s GLP-1 Lead Faces New Pressure From Novo’s Weight-Loss Pill

Eli Lilly Shifts to Access-First Strategy on GLP-1 Strength